1. Home
  2. RIGL vs GPRE Comparison

RIGL vs GPRE Comparison

Compare RIGL & GPRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • GPRE
  • Stock Information
  • Founded
  • RIGL 1996
  • GPRE 2004
  • Country
  • RIGL United States
  • GPRE United States
  • Employees
  • RIGL N/A
  • GPRE N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • GPRE Major Chemicals
  • Sector
  • RIGL Health Care
  • GPRE Industrials
  • Exchange
  • RIGL Nasdaq
  • GPRE Nasdaq
  • Market Cap
  • RIGL 335.5M
  • GPRE 289.7M
  • IPO Year
  • RIGL 2000
  • GPRE N/A
  • Fundamental
  • Price
  • RIGL $18.98
  • GPRE $7.98
  • Analyst Decision
  • RIGL Buy
  • GPRE Buy
  • Analyst Count
  • RIGL 5
  • GPRE 7
  • Target Price
  • RIGL $36.40
  • GPRE $10.42
  • AVG Volume (30 Days)
  • RIGL 206.5K
  • GPRE 2.1M
  • Earning Date
  • RIGL 08-05-2025
  • GPRE 08-05-2025
  • Dividend Yield
  • RIGL N/A
  • GPRE N/A
  • EPS Growth
  • RIGL N/A
  • GPRE N/A
  • EPS
  • RIGL 2.08
  • GPRE N/A
  • Revenue
  • RIGL $203,077,000.00
  • GPRE $2,463,097,000.00
  • Revenue This Year
  • RIGL $14.41
  • GPRE $2.90
  • Revenue Next Year
  • RIGL $15.97
  • GPRE $1.54
  • P/E Ratio
  • RIGL $9.41
  • GPRE N/A
  • Revenue Growth
  • RIGL 70.16
  • GPRE N/A
  • 52 Week Low
  • RIGL $8.10
  • GPRE $3.14
  • 52 Week High
  • RIGL $29.82
  • GPRE $18.14
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 45.79
  • GPRE 86.79
  • Support Level
  • RIGL $18.24
  • GPRE $5.60
  • Resistance Level
  • RIGL $19.38
  • GPRE $5.88
  • Average True Range (ATR)
  • RIGL 0.77
  • GPRE 0.39
  • MACD
  • RIGL -0.04
  • GPRE 0.14
  • Stochastic Oscillator
  • RIGL 43.64
  • GPRE 95.62

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About GPRE Green Plains Inc.

Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.

Share on Social Networks: